EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2 -related schwannomatosis and progressive vestibular schwannoma

Scott R Plotkin iD, Jeffrey Allen, Girish Dhall iD, Jian L Campian, D Wade Clapp iD, Michael J Fisher, Rakesh K Jain, James Tonsgard iD, Nicole J Ullrich iD, Coretta Thomas, Lloyd J Edwards iD, Bruce Korf iD und 3 weitere

Neuro-Oncology · 03.08.2023 · 25 (8) · 1498-1506

DOI: 10.1093/neuonc/noad066 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Neuro-Oncology, online erschienen am 03.04.2023. Verfasst von Scott R Plotkin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Neuroma, Acoustic, Hearing Loss, Neurofibromatosis 2. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prospective data on maintenance therapy with bevacizumab for persons with NF2-related schwannomatosis (NF2-SWN) is lacking. In this prospective multicenter phase II study, we evaluated the efficacy, safety, and tolerability of bevacizumab for maintenance therapy in children and adults with NF2-SWN and hearing loss due to vestibular schwannomas (VS).

Methods

Following induction therapy, participants received bevacizumab 5 mg/kg every 3 weeks for 18 months. Participants were monitored for changes in hearing, tumor size, and quality of life (QOL), and for adverse events. Hearing loss was defined as a statistically significant decline in word recognition score (WRS) or pure-tone average compared to the study baseline; tumor growth was defined as >20% increase in volume compared to baseline.

Results

Twenty participants with NF2-SWN (median age 23.5 years; range, 12.5–62.5 years) with hearing loss in the target ear (median WRS 70%, range 2%–94%) received maintenance bevacizumab. Freedom from hearing loss in the target ear was 95% after 48 weeks, 89% after 72 weeks, and 70% after 98 weeks. Freedom from tumor growth in the target VS was 94% after 48 weeks, 89% after 72 weeks, and 89% after 98 weeks. NF2-related QOL remained stable for 98 weeks whereas tinnitus-related distress decreased. Maintenance bevacizumab was well tolerated, with 3 participants (15%) discontinuing treatment due to adverse events.

Conclusions

Maintenance bevacizumab (5 mg/kg every 3 weeks) is associated with high rates of hearing and tumor stability during 18 months of follow-up. No new unexpected adverse events related to bevacizumab were identified in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroma, AcousticHearing LossNeurofibromatosis 2AdultYoung AdultBevacizumabNeurofibromatosesChildProspective StudiesHumansTreatment OutcomeSkin NeoplasmsQuality of LifeNeurilemmoma

Stichwörter der Autor:innen

NF2bevacizumabmaintenanceneurofibromatosis 2vestibular schwannoma

Substanzen

Bevacizumab

Autor:innen und Institutionen

  • Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • NYU Langone Health, New York, New York, USA.
  • University of Southern California, Los Angeles, California, USA.
  • Washington University, St. Louis, Missouri, USA.
  • University of Indiana, Indianapolis, Indiana, USA.
  • The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Scott R Plotkin, Girish Dhall, D Wade Clapp, James Tonsgard, Nicole J Ullrich, Lloyd J Edwards, Bruce Korf, Roger Packer, Matthias A Karajannis, Jaishri O Blakeley

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • NICHD NIH HHS
  • Dana-Farber/Harvard Cancer Center
  • Department of Defense

Zitieren

APA

Plotkin, S. R., Allen, J., Dhall, G., Campian, J. L., Clapp, D. W., Fisher, M. J., Jain, R. K., Tonsgard, J., Ullrich, N. J., Thomas, C., Edwards, L. J., Korf, B., Packer, R., Karajannis, M. A., & Blakeley, J. O. (2023). Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2 -related schwannomatosis and progressive vestibular schwannoma. Neuro-Oncology, 25(8), 1498-1506. https://doi.org/10.1093/neuonc/noad066

Vancouver

Plotkin SR, Allen J, Dhall G, Campian JL, Clapp DW, Fisher MJ, et al. Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2 -related schwannomatosis and progressive vestibular schwannoma. Neuro-Oncology. 2023;25(8):1498-1506. doi:10.1093/neuonc/noad066

BibTeX
@article{Plotkin2023,
  author = {Plotkin, Scott R and Allen, Jeffrey and Dhall, Girish and Campian, Jian L and Clapp, D Wade and Fisher, Michael J and Jain, Rakesh K and Tonsgard, James and Ullrich, Nicole J and Thomas, Coretta and Edwards, Lloyd J and Korf, Bruce and Packer, Roger and Karajannis, Matthias A and Blakeley, Jaishri O},
  title = {Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2 -related schwannomatosis and progressive vestibular schwannoma},
  journal = {Neuro-Oncology},
  year = {2023},
  volume = {25},
  number = {8},
  pages = {1498--1506},
  doi = {10.1093/neuonc/noad066}
}
Kostenlos starten →